CO2022014684A2 - Variantes de anticuerpos felinos - Google Patents

Variantes de anticuerpos felinos

Info

Publication number
CO2022014684A2
CO2022014684A2 CONC2022/0014684A CO2022014684A CO2022014684A2 CO 2022014684 A2 CO2022014684 A2 CO 2022014684A2 CO 2022014684 A CO2022014684 A CO 2022014684A CO 2022014684 A2 CO2022014684 A2 CO 2022014684A2
Authority
CO
Colombia
Prior art keywords
antibody variants
feline antibody
feline
relates
variants
Prior art date
Application number
CONC2022/0014684A
Other languages
English (en)
Inventor
Lisa Marie Bergeron
Henry Luis Campos
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CO2022014684A2 publication Critical patent/CO2022014684A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere generalmente a variantes de anticuerpos felinos y usos de estos. Específicamente, la invención se refiere a mutaciones en la región constante del anticuerpo felino para mejorar su semivida y otras características.
CONC2022/0014684A 2020-04-17 2022-10-18 Variantes de anticuerpos felinos CO2022014684A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063011491P 2020-04-17 2020-04-17
PCT/US2021/027839 WO2021212084A1 (en) 2020-04-17 2021-04-16 Feline antibody variants

Publications (1)

Publication Number Publication Date
CO2022014684A2 true CO2022014684A2 (es) 2022-11-08

Family

ID=75870744

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0014684A CO2022014684A2 (es) 2020-04-17 2022-10-18 Variantes de anticuerpos felinos

Country Status (16)

Country Link
US (1) US20240067730A1 (es)
EP (1) EP4136109A1 (es)
JP (1) JP2023522030A (es)
KR (1) KR20230005158A (es)
CN (1) CN115667300A (es)
AU (1) AU2021257355A1 (es)
BR (1) BR112022020631A2 (es)
CA (1) CA3176434A1 (es)
CL (2) CL2022002856A1 (es)
CO (1) CO2022014684A2 (es)
EC (1) ECSP22080858A (es)
IL (1) IL297290A (es)
MX (1) MX2022012793A (es)
PE (1) PE20230348A1 (es)
TW (1) TW202204404A (es)
WO (1) WO2021212084A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3906259A2 (en) 2019-01-03 2021-11-10 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
CN115867572A (zh) 2020-05-11 2023-03-28 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物和使用方法
MX2023000500A (es) 2020-07-10 2023-04-12 Invetx Inc Composiciones para aumentar la semivida de un agente terapeutico en felinos y modos de uso.
US20230382986A1 (en) * 2020-09-29 2023-11-30 Zoetis Services Llc Feline antibody variants

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013184871A1 (en) 2012-06-06 2013-12-12 Zoetis Llc Caninized anti-ngf antibodies and methods thereof

Also Published As

Publication number Publication date
AU2021257355A1 (en) 2022-11-03
IL297290A (en) 2022-12-01
CL2022002856A1 (es) 2023-06-02
KR20230005158A (ko) 2023-01-09
BR112022020631A2 (pt) 2022-11-29
US20240067730A1 (en) 2024-02-29
PE20230348A1 (es) 2023-03-02
TW202204404A (zh) 2022-02-01
CA3176434A1 (en) 2021-10-21
WO2021212084A1 (en) 2021-10-21
CL2023003376A1 (es) 2024-04-19
EP4136109A1 (en) 2023-02-22
CN115667300A (zh) 2023-01-31
ECSP22080858A (es) 2023-01-31
JP2023522030A (ja) 2023-05-26
MX2022012793A (es) 2022-11-07

Similar Documents

Publication Publication Date Title
CO2022014695A2 (es) Variantes de anticuerpos caninos
CO2022014684A2 (es) Variantes de anticuerpos felinos
CO2023007829A2 (es) Mutaciones en regiones constantes de anticuerpos felinos
CO2023004102A2 (es) Variantes de anticuerpos caninos
CO2023007146A2 (es) Variantes de anticuerpos bovinos
BR112018001955A2 (pt) anticorpos monoclonais contra bcma
CL2024001562A1 (es) Mutaciones en regiones constantes de anticuerpos caninos.
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
EA201991736A1 (ru) Антитело против оболочечного herv-k и его применение
CL2024000321A1 (es) Antagonistas de lpar1 y usos de estos
CO2023004107A2 (es) Variantes de anticuerpos felinos
EA202192101A1 (ru) Соединения и их применение
EA202192532A1 (ru) Мирикизумаб для применения в способе лечения болезни крона
TR202019577U4 (tr) Abajur bağlanti aparatinda yeni̇li̇k
EA201991614A1 (ru) СПЕЦИФИЧНЫЕ К ИЗОФОРМЕ, ПЕРМИССИВНЫЕ ПО ОТНОШЕНИЮ К КОНТЕКСТУ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ
TR202104726A2 (tr) Köfte form maki̇nasinda yeni̇li̇k
TR201820310U5 (tr) Çay kazaninda (maki̇nesi̇nde) yeni̇li̇k
TR201820317U5 (tr) Çay kazaninda (maki̇nesi̇nde) yeni̇li̇k
TR202009132U5 (tr) Konfeti̇lerde yeni̇li̇k
EA202193086A1 (ru) Ингибиторы аутофагии на основе фениламинопиримидинамида и способы их применения
CL2019001358S1 (es) Álbum de colección.
TR200503234U (tr) Hamur açma makinası.